Evaluation of the Highly Variable Agomelatine Pharmacokinetics in Chinese Healthy Subjects to Support Bioequivalence Study

Qi Pei1, Yan Wang2, Zhe-Yi Hu3, Shi-Kun Liu3, Hong-Yi Tan1, Cheng-Xian Guo1, Ran-Ran Zhang1, Yu-Xia Xiang1, Jie Huang1, Lu Huang1, Hong Yuan1, Guo-Ping Yang1*

1 Center of Clinical Pharmacology, the Third Xiangya Hospital, Central South University, Changsha, Hunan, China, 2 Department of pharmacy, Changde First People’s Hospital, Changde, Hunan, China, 3 Department of pharmacy, the Third Xiangya Hospital, Central South University, Changsha, Hunan, China, 4 Department of Clinical Pharmacy, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee, United States of America

Abstract

Objectives: We aim to obtain the intra-subject coefficient of variability of a highly variable antidepressant agomelatine in humans, and propose an adjusted bioequivalence assessment strategy.

Methods: A single-dose, randomized crossover design was conducted in four periods (reference administered thrice, placebo administered once) separated by seven days. A validated LC-MS/MS assay was used to measure drug concentrations in serial blood samples.

Results: The intra-subject coefficient of variability was calculated using the residual variance of ANOVA analysis, and the results for Cmax and AUC0-t was 78.34% and 43.52%, respectively, in Chinese healthy subjects. The sample size required for standard BE study were 124(192, 340) if the expected deviation between the reference and generic products was set to 0 (5%, 10%).

Conclusions: Agomelatine meets the criteria for highly variable drug in Chinese healthy male subjects, and the traditional BE criteria for agomelatine needs to be adjusted to alleviate the resource and ethical burden of using a large numbers of subjects in clinical trials. Our clinical data on the intra-subject variability of agomelatine PK in Chinese healthy population enables to adjust bioequivalence (BE) assessment approach for agomelatine based on the RSABE approaches recommended by regulatory agencies.

Trial Registration: ChiCTR.org ChiCTR-TTRCC-13003835

Introduction

Agomelatine brings a new concept to the antidepressant treatment. Compared to the other antidepressant drugs (e.g. mianserin and mirtazapine), agomelatine owns its melatonin (MT1 and MT2) agonist properties and a serotonin 5-HT2C antagonist effect simultaneously [1,2]. The recommended oral administration dose is 25 mg once daily [3]. The existing data on agomelatine metabolism, bioavailability and pharmacokinetics in Caucasian indicate that the absorption of agomelatine is rapid with the median tmax 0.75–1.5 hours and almost complete with at least 80% intestinal absorption [4,5]. However its absolute oral bioavailability is low, approximately 3–4%, with highly variable (estimated to 104%), which has been explained by its extensive first pass metabolism [3].

For new generic agomelatine products/formulation with clinical trial permission of China Food and Drug Administration (CFDA), bioequivalence (BE) evaluation is one of the pivotal clinical studies required in support of its marketing application. Due to the highly variable feature, a standard number of subjects (e.g., 18–24) may not be able to demonstrate the bioequivalence of the generic products and their corresponding reference products using a two-way crossover design. In order to obtain adequate statistical power to meet BE limits, the subjects number for BE study of highly variable drugs need to be calculated based on the intra-subject coefficient of variability (CV) of pharmacokinetic (PK) parameters (Cmax and AUC) of reference products [6,7,8]. To our knowledge, the intra-subject CV data of agomelatine in Chinese healthy volunteers has not been reported. So we aim to investigate the
intra-subject CV of agomelatine in Chinese healthy volunteers, and propose an adjusted BE assessment strategy for agomelatine.

**Methods**

The protocol for this trial and supporting CONSORT checklist are available as supporting information; see Checklist S1 and Protocol S1.

**Ethics Statement**

The study was approved by the Ethics Committee of the Third Xiangya Hospital of Central South University, Changsha, Hunan P. R. China (approved number: 12066), on September 7, 2012, name: The intra-subject coefficient of variability of agomelatine in healthy Chinese and registered in the Chinese Clinical Trial Registry (registration number: ChiCTR-TTRCC-13003835). All clinical investigation must have been conducted according to the principles expressed in the Declaration of Helsinki. Written informed consents were obtained from all subjects before enrollment and overall clinical trial procedures abided by the Good Clinical Practice of the International Conference on Harmonization (ICH-GCP).

**Subjects**

Suitable subjects were healthy males between 18 and 40 years of age with a Body Mass Index (BMI) between 19 and 25 kg·m⁻². Subjects were judged to be eligible for the study when no clinical significant abnormal findings existed on a complete medical examination consisting of medical history, physical examination, urine analysis.

**Study Design**

This was a single-blind, two-treatment, four-period, four-sequence crossover design study (R-R-R-R, R-R-P-R, R-P-R-R, P-R-R-R). After 10-hour overnight fast in the ward, all subjects (n = 16) were randomly assigned to four groups and received a single oral 25 mg of agomelatine (reference, Valdoxan, Servier, France) in three of the four treatment periods and placebo in the other treatment period. Each study period was separated by 7 days. The placebo group was set to conduct safety evaluation.

Each dose was administrated with 250 ml of tap water. Light diets were served 4 and 10 hours after taking the dose. The same standardized diets were provided in all four periods. During each study day, no food except the standardized meals served was permitted. Neither caffeine-containing nor alcohol beverages were allowed until 24 hours after dosing. Smoking was forbidden during the same interval after the dose administration. Neither prescription nor over-the-counter drugs were allowed during participation in the study. No water drinking was required within 2 hours before and after the dose administration.

Serial blood samples, using anticoagulant tube were collected at 0, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 5.0, 6.0, 8.0, 10.0, 12.0 and 16.0 hours after dosing. The blood samples were centrifuged and the plasma samples were stored at −20°C until analyzed.

Safety was evaluated through the assessment of adverse events (AEs), vital signs and standard laboratory evaluation.

**Analytical Assay**

An Agilent 1260 HPLC system (Agilent Technologies, Germany) was used to analyze the plasma samples. Mass spectrometric detection was performed on an Agilent 6460 triple quadrupole mass spectrometry (Agilent Technologies, Germany) using multiple reaction monitor (MRM). Data processing was performed on Agilent MassHunter Workstation Software (Agilent Technologies, Germany).

The HPLC separation was performed on an Agilent Phenomenex C18 column (4.6×150 mm, 5 μm) (Phenomenex, USA) by a mobile phase consisting of 3 mM ammonium formate (80:20, v/v) at 35°C, and was delivered at a flow rate of 0.8 mL/min.

The typical operating source conditions for MS scan in positive ESI mode were optimized such that the capillary voltage was 4.0 kV and the skimmer at, 60 V. Nitrogen was used as the drying (350°C; 11 L/min) and nebulizer (45 psi) gas.

The multiple reaction monitoring (MRM) conditions were m/z 244→185.1 and m/z 386.1→122.0 for analyte and IS, respectively. The detection parameters were optimized as follows: Collision energy, 10 eV for analyte and 21 eV for the IS; ionization voltage, 80 V for analyte and 95 V for the IS.

The analytical assay involved the addition of a 30 μL phenacetin (internal standard, IS) and 300 μL of plasma, followed by extraction into 4 mL of extraction solvent, ethyl acetate. The sample was centrifuged for 5 minutes and the organic phase was transferred into a polypropylene tube and evaporated to dryness at 45°C under a gentle stream of nitrogen. The residue was reconstituted in 200 μL of mobile phase, after high speed centrifugation, 3 μL was injected onto the LC-MS/MS system.

The response was linear in the concentration range, 0.04096 to 10 μg·L⁻¹, with a coefficient of determination (r²)>0.997. The limit of quantitation was 0.04096 μg·L⁻¹ and the inter-assay coefficient of variation at this concentration was 6.4%. The intra-assay and inter-assay precision of the quality control samples were <10%; the accuracy was within 15% of the nominal concentration. The methods were also validated for selectivity, carry-over effect, matrix effects, extraction recoveries and stability. All the validation results meet the accepted criteria according to the EMA guidance on bioanalytical method validation [9].

**Data Analysis**

From the measured plasma concentration data, the area under the plasma concentration vs. time curve from zero to the last

| Race          | Cmax(ng/ml)  | AUC0-t (ng·h·ml⁻¹) | tmax (h) | t1/2 (h) |
|---------------|--------------|--------------------|----------|----------|
| Chinese (n = 16) | 9.3±15.9     | 11.1±14.3          | 1 (0.5–4)| 0.96±0.45|
| westerner (n = 8) | 3.0±2.8      | 4.9±5.6            | 1 (0.5–4)| 0.9±0.4  |

*mean±SD; **median (min-max).

doi:10.1371/journal.pone.0109300.t001
Table 2. $C_{max}$ and $AUC_{(0-t)}$ of the three same separated treatment in each healthy Chinese volunteer following oral administration of 25 mg of agomelatine reference tablets (n = 16).

| Subjects | $C_{max}$(ng/mL) | $AUC_{(0-t)}$ (ng/mL · h) |
|----------|------------------|-----------------------------|
|          | $R_1$ | $R_2$ | $R_3$ | Mean | SD  | CV (%) | $R_1$ | $R_2$ | $R_3$ | Mean | SD  | CV (%) |
| 1        | 0.40  | 1.51  | 0.74  | 0.88  | 0.57 | 64.26  | 0.61  | 1.90  | 1.14  | 1.22  | 0.65 | 53.29 |
| 2        | 0.48  | 0.20  | 0.59  | 0.42  | 0.20 | 47.92  | 0.84  | 0.32  | 0.73  | 0.63  | 0.27 | 42.98 |
| 3        | 1.55  | 2.08  | 2.68  | 2.10  | 0.56 | 26.86  | 4.55  | 3.77  | 6.86  | 5.06  | 1.61 | 31.74 |
| 4        | 3.82  | 4.88  | 4.01  | 4.23  | 0.56 | 13.34  | 7.95  | 8.15  | 4.73  | 6.94  | 1.92 | 27.99 |
| 5        | 19.02 | 25.91 | 27.86 | 24.26 | 4.64 | 19.14  | 27.82 | 26.28 | 37.93 | 30.68 | 6.33 | 20.63 |
| 6        | 1.77  | 8.41  | 2.18  | 4.12  | 3.72 | 90.27  | 4.87  | 7.81  | 3.18  | 5.29  | 2.34 | 44.24 |
| 7        | 3.48  | 2.94  | 9.51  | 5.31  | 3.64 | 68.67  | 9.16  | 8.58  | 10.74 | 9.49  | 1.12 | 11.77 |
| 8        | 2.50  | 0.54  | 0.87  | 1.34  | 1.10 | 82.57  | 1.98  | 1.34  | 1.50  | 1.61  | 0.33 | 20.69 |
| 9        | 7.72  | 19.07 | 9.28  | 12.02 | 6.15 | 51.17  | 14.69 | 18.73 | 12.28 | 15.23 | 3.25 | 21.36 |
| 10       | 8.70  | 4.45  | 6.92  | 6.69  | 2.13 | 31.91  | 10.79 | 7.33  | 7.80  | 8.64  | 1.88 | 21.77 |
| 11       | 5.25  | 12.63 | 11.68 | 9.85  | 4.01 | 40.72  | 9.73  | 12.69 | 10.48 | 10.97 | 1.54 | 14.02 |
| 12       | 9.71  | 4.53  | 11.63 | 8.63  | 3.67 | 42.57  | 15.15 | 9.81  | 12.58 | 12.51 | 2.67 | 21.32 |
| 13       | 18.93 | 5.85  | 1.78  | 8.85  | 8.96 | 101.27 | 14.03 | 7.10  | 4.11  | 8.42  | 5.09 | 60.47 |
| 14       | 51.84 | 14.53 | 96.92 | 54.43 | 41.26 | 75.80 | 53.80 | 31.31 | 77.13 | 54.08 | 22.91 | 42.37 |
| 15       | 2.44  | 1.49  | 0.48  | 1.47  | 0.98 | 66.77  | 2.34  | 3.67  | 1.65  | 2.56  | 1.02 | 40.07 |
| 16       | 8.72  | 4.27  | 0.95  | 4.65  | 3.90 | 83.89  | 7.17  | 4.58  | 1.40  | 4.38  | 2.89 | 65.87 |

doi:10.1371/journal.pone.0109300.t002
measurable time point (AUC0-t) was calculated by the linear trapezoidal method. The maximum plasma concentration (Cmax) was obtained directly from the plasma concentration-time curve. Analysis of variance (ANOVA) [10], using period, sequence as fixed model effects, and subject nested within sequence as random effects, were performed on the natural logarithmic transformations of Cmax and AUC for the 3 same separated treatment periods using the GLM (General Linear Models) procedure of SPSS (Version 18.0, Chicago, IL, USA). Based on the literature [8,11,12], the mean square error (MSE) was used to estimate the intra-subject variation. The intra-individual CV was related to the MSE on the logarithmic scale as follows:

$$CV\% = \sqrt{\exp(\text{MSE})-1} \times 100\%$$  \hspace{1cm} (1)

Sample sizes for the agomelatine BE study were calculated using the following formula [13]:

$$N \geq 2\left[\frac{\sqrt{\frac{\alpha^2}{2}}}{\sigma_1} + \frac{\sqrt{\frac{\beta^2}{2}}}{\sigma_2}\right]^2 \frac{CV^2}{(\Delta-\theta)^2}$$  \hspace{1cm} (2)

where $\Delta$ is indicative of BE limit, according to the current CFDA guidelines, usually set to $\pm 20\%$ for AUC and $\pm 25\%$ [14] for Cmax in most BE studies; $\theta = \left[\frac{\mu_T-\mu_R}{\mu_R}\right]*100$ is the difference in average bioavailability between the test and reference formulations; $\sigma$ is the total number of subjects required to achieve a 1-$\beta$ (0.8 if $\beta = 0.2$) power at the $\alpha$ (e.g. 0.05) significance level.

**Results**

**Demographics and safety**

Sixteen healthy male volunteers (fifteen Han nationality and one Tuja minority), age 19–29 years (mean, 23 years), height 1.62–1.75 m (mean, 1.68 m), weight 50.5–68 kg (mean, 57 kg), BMI 19.1–22.2 kg·m$^{-2}$ (mean, 20.3 kg·m$^{-2}$) participated in the study. There were no protocol violations or serious AEs observed during the study. Nine of the 16 subjects experienced a total of 11 AEs (9 were mild and 2 were moderate). The common types of AEs were somnolence (2 events) and tiredness (2 events), followed by the foot heel injury (1 event), amygdalitis (1 event), vasovagal reaction (1 event), globulin content decreased (1 event), aspartate aminotransferase and alanine aminotransferase increased (1 event), urticaria papulosa (1 event), rash (1 event). Several AEs (4 events) were considered to be probably related to the study medication. No clinically significant abnormalities on vital sign measurements or electrocardiographic recordings were reported. There was no significant difference in safety between the placebo group and experimental group.

**Pharmacokinetic parameters**

Main pharmacokinetic (PK) parameters of agomelatine(25 mg oral) in 16 Chinese healthy male volunteers summarized in Table 1, where the data in Caucasian is provided for comparison [3]. There are significant ethnic differences between Chinese and Caucasian in the rate of absorption (Cmax) and the extent of absorption (AUC0-t) while no ethnic difference in tmax and t1/2. Less obvious first-pass effect in Chinese may partially account for why both Cmax and AUC of Chinese healthy male were much higher than those of the Caucasian. Cmax and AUC0-t in each healthy Chinese volunteer of the three same separated treatment following oral agomelatine reference tablets were presented in Table 2.

**Concentration-time curves**

Mean plasma concentration-time profiles of agomelatine from 16 Chinese subjects after a single oral dose of 25 mg agomelatine reference tablet were illustrated in Figure 1. The concentration-time profiles differed greatly in three periods. Particularly, double-peak phenomenon was observed for two of the profiles (R1 and R3), indicating notable intra-individual variability.

**Intra-subject variability**

The Cmax and AUC0-t values after natural logarithmic transformation and intra-subject CV (the ration of the standard deviation to the mean) were presented in Table 2.
deviations to mean) of all 16 subjects on each occasion were shown in Figure 2. The overall intra-subject CV was calculated by taking the square root of the MSE on the logarithmic scale and multiplying by 100% as [eq.1]. There were notable intra-subject variabilities in AUC₀⁻₄ (CV = 43.52%) and Cₘₐₓ (CV = 78.34%).

As the absolute values of AUC₀⁻₄ or Cₘₐₓ for some subjects (e.g., subject 1, 2, 8 and 15) in different periods are close to each other, especially due to low values the relative CV (the ratio of standard deviation to mean) was used in Figure 2. The intra-subject CV of Cₘₐₓ varied from 13.34% to 101.27% (average 57.02%, 14 of 16

Figure 2. Cₘₐₓ(A) and AUC₀⁻₄ (B) values after natural logarithmic transformation and intra-subject CV (the ratio of the standard deviations to mean) (n = 16).
doi:10.1371/journal.pone.0109300.g002
subjects >30%) and the AUC\textsubscript{0-t} varied from 11.77% to 65.87% (average 33.82%, 8 of 16 subjects >30%).

Sample size calculation for standard BE study

Table 3 presents the required total sample size to achieve an 80% power for $\theta$ from 0 to 10% by increment of 5%. If expected deviation was 0 (5%, 10%) between the reference and generic products, the sample size required by standard BE study was 124 (192, 340).

Sample size calculation for reference-scaled average bioequivalence (RSABE)

In this study, C\textsubscript{max} was chosen to be the basis for the sample size calculation for the higher variability than AUC. Table 4 shows the sample sizes required for the design of agomelatine BE studies using RSABE approaches. The ratios of geometric means (GMR) are considered within the range of 0.90 to 1.00. Based on the EMA approach, the minimum number of subjects for the 3-period partially replicating design is 72, 54 and 51 for GMR 0.90, 0.95 and 1.00, respectively. Using the similar approach, the number of subjects needed for the 4-period replicated design is 50, 38 and 35, respectively. Based on the FDA approach, the minimum number of subjects for the 3-period partially replicating design is 40, 29 and 29 for GMR 0.90, 0.95 and 1.00, respectively. For the 4-period replicated design, the number of subjects is 29, 21 and 20, respectively. Haidar et al. [15] suggested that the inclusion of at least 24 subjects were required for Caucasian BE study. So, the same 24 subjects could be considered as the absolute minimum in Chinese BE study.

Discussion

This study reported the intra-subject CV data of agomelatine pharmacokinetics in Chinese healthy male subjects (within-subject variability is >30%) for the first time, demonstrating agomelatine meets the criteria for highly variable drug in Chinese subjects. Traditional BE assessment approach needs to be adjusted for highly variable drugs based on essential pilot data. Although agomelatine pilot data is available in literature for Caucasians [3], it cannot be directly applied to the BE study in other populations due to ethnic differences, which was demonstrated in the pharmacokinetic parameters of agomelatine by comparing the current Chinese study to the Caucasian study.

For highly variable drug of agomelatine, too large sample size required by standard BE study. Therefore, adjustment of the traditional BE criteria and study design is needed to alleviate the resource and ethical burden of using a large number of subjects in clinical trials. To lower sample size required for highly variable drugs BE study, the regulatory agencies, Food and Drug Administration (FDA) and European Medicines Agency (EMA), have recommended the RSABE approach, whereby the BE acceptance limits are scaled to the variability of the reference product [7,15,16].

FDA has posted Guidance for Industry (Bioequivalence Recommendations for Progesterone Oral Capsule [17], Warfarin Sodium [18]) which providing step-by-step instructions on how to analyze data using RSABE. Meanwhile, Tothfalusi L [19] conducted massive simulations, from which sample sizes needed for BE assessment of highly variable drugs with different with-subject variable were calculated by using the RSABE approaches of FDA and EMA. It presented the detailed sample size in four tables based on different power (80%, 90%) and intra-subject CV (30%~80%).

Therefore, our work is a pilot study to estimate the BE study sample size to facilitate generic application based on the new RSABE approach, with significance of providing intra-subject CV in Chinese healthy male.

Intra-subject CV was calculated based on the formula CV = $\sqrt{\exp (MSE)-1}$ and related to the MSE obtained by the GLM procedure of SPSS in this study. Several studies [10,11]

Table 3. Sample size calculation for standard agomelatine bioequivalence study in Chinese healthy volunteers.

| PK Parameters | $\alpha$ | $1-\beta$ | CV (%) | $\Delta$ (%) | $\theta$ (%) | N  |
|---------------|---------|--------|--------|-------------|-------------|----|
| AUC\textsubscript{0-t} | 0.05    | 0.80   | 43.52  | 0.20        | 0           | 62 |
|               |         |        |        |             |             | 5  |
|               |         |        |        |             |             | 10 |
|               |         |        |        |             |             | 242|
| C\textsubscript{max} | 0.05    | 0.80   | 78.34  | 0.25        | 0           | 124|
|               |         |        |        |             |             | 5  |
|               |         |        |        |             |             | 192|
|               |         |        |        |             |             | 10 |
|               |         |        |        |             |             | 340|

Table 4. Sample sizes enquired for BE study of agomelatine using EMA and FDA approaches.

| Regulatory Agencies | Design | Ratio of geometric means (GMR) | 0.90 | 0.95 | 1.00 |
|---------------------|--------|--------------------------------|------|------|------|
| EMA                 | 3-period study | 72*   | 54   | 51   |
|                     | 4-period study | 50    | 38   | 35   |
| FDA                 | 3-period study | 40    | 29   | 27   |
|                     | 4-period study | 29    | 21   | 20   |

*Number of human subjects.
about intra-subject variance \((\sigma_i^2)\) were similar to our work, such as in the assumption of model for a standard 2×2 crossover design, that the \(\sigma_i^2\) was indicative of the residual variance and calculated by using ANOVA. Unlike the 3 same separated treatments of this work, the fixed model effect of the classical 2×2 crossover included formulation. In the FDA guidance on progesterone BE, the formula of \(CVRWR = \left[\exp\left(\sigma_i^2/W_i\right)\right]^{1/2}\) was used to calculate the intra-subject CV. \(s_i^2\), the population within-subject variance of the reference formulation. The guidance recommends researchers to adopt PROC GLM and MIXED of SAS for 3-way and 4-way replicated BE studies, respectively [17].

A number of factors can contribute to the high inter-individual variability in agomelatine pharmacokinetics. Agomelatine undergoes an extensive first pass metabolism after oral administration resulting in remarkable low systemic availability. CYP1A2 is the major enzyme (90%) involved in the hepatic metabolism of agomelatine, and smoking was shown to reduce plasma concentrations three- to fourfold due to induction of CYP1A2. Subjects with smoking habit would contribute to the high variability in exposures of agomelatine. Furthermore, oral administrated agomelatine is extensively distributed throughout the body which could be another factor contributing to high inter-individual variability [3,20].

Recently, Song [21] found that several CYP1A2 SNPs (rs762531, rs2407890 and rs2472304) might be associated with the marked interindividual variability of agomelatine. Whether these polymorphisms affect the intra-subject variability of agomelatine PK in Chinese healthy male was not considered in our study, which was a limitation in this article.

Conclusions

Agomelatine meets the criteria for highly variable drug in Chinese subjects, and the traditional BE criteria for agomelatine needs to be adjusted to alleviate the resource and ethical burden of using a large numbers of subjects in clinical trials. Our clinical data on the intra-subject variability of agomelatine PK in Chinese healthy population recommends adjusting bioequivalence (BE) assessment approach for agomelatine based on the RSABE approaches recommended by regulatory agencies.

Acknowledgments

We express sincere thanks to the group numbers of our laboratory for their fully assist during the process of this work. My colleague Yan Wang and Qi Pei edited the manuscript.

Supporting Information

Figure S1  Agomelatine CONSORT Flow Diagram. (TIFF)
Checklist S1  CONSORT checklist. (DOCX)
Protocol S1  Study on the Variability of Agomelatine. (DOC)
Protocol S2  Chinese Version protocol. (DOC)

Author Contributions

Conceived and designed the experiments: GY PQ. Performed the experiments: YW RRZ LH. Analyzed the data: YW QQ RRZ LH. Contributed reagents/materials/analysis tools: HYT CXG YXX JH. Wrote the paper: YW QQ. Involved in the modification of the manuscript: ZYHL SKL HY.

References

1. Koesters M, Guaniga G, Cipriani A, Becker T, Barbui C (2013) Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials. Br J Psychiatry 203(3): 179–187.
2. Heun R, Aleskas A, Boyer P, Gimenez-Montesinos N, Pontes-Saore F, et al. (2013) The efficacy of agomelatine in elderly patients with recurrent major depressive disorder: a placebo-controlled study. J Clin Psychiatry 74(6): 387–394.
3. European Medicines Agency. (2008) CHMP Assessment Report for Valdoxan. Available: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000916/WC500038315.pdf. Accessed: 2013 Oct 31.
4. Wang X, Zhang D, Lin M, Zhao H, Du A, et al. (2014) LC-MS/MS method for the determination of agomelatine in human plasma and its application to a pharmacokinetic study. Bionmed Chromatogr 28(2): 218–222.
5. Patil SR, Nerurkar KK, Kalamkar AM, Pukule V, Mangaonkar KV, et al. (2012) Validated LC-MS/MS method for quantification of agomelatine in human plasma and its application in a pharmacokinetic study. J Mass Spectrom 47(1): 23–28.
6. Haidar SH, Makhlof F, Schuirmann DJ, Hyslop T, Davit B, et al. (2008) Evaluation of a scaling approach for the bioequivalence of highly variable drugs. AAPS J 10(3): 450–454.
7. David BM, Conner DP, Fabian-Frisch B, Haidar SH, Jiang X, et al. (2008) Highly variable drugs: observations from bioequivalence data submitted to the FDA for new generic drug applications. AAPS J 10(1): 148–156.
8. Milhka KK, Ravsoo MJ, Hubbard JW (2005) The bioequivalence of highly variable drugs and drug products. Int J Clin Pharmacol Ther 43(4): 485–490.
9. European Medicines Agency. (2011) Guidance on bioanalytical method validation. Available: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109086.pdf. Accessed: 2014 Jul 24.
10. Almeida S, Filipe A, Gich I, Antonijonan R, et al. (2006) Comparative study on the bioequivalence of two formulations of pravastatin. Data from a crossover, randomised, open-label bioequivalence study in healthy volunteers. Arzneimitteinforschung 36(2): 70–75.
11. Blume HH, Midha KK (1995) Bio-International 92, conference on bioavailability, bioequivalence, and pharmacokinetic studies. J Pharm Sci 82(11): 1106–1109.
12. Food and Drug Administration. (2004) Department of health and human services. Available: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DrugsforSpecialPatientpopulations/UCM201283.pdf. Accessed: 2013 Oct 31.
13. Liu JP, Chow SC (1992) Sample size determination for the two one-sided tests procedure in bioequivalence. J Pharmaco kinet Biopharm 20(1): 101–104.
14. China Food and Drug Administration. (2005) Guidance on the Chemical pharmaceutical preparations of human bioavailability and bioequivalence study. Available: http://www.sda.gov.cn/Directory/WS01/Images/ebRgIqKanwWzxByMmA5c6z6Ae99PD6oa6z6mu9yNCnflNTRnLz94Unh9uUdTxEpBZzg=pdf.pdf. Accessed: 2013 Oct 31.
15. Haidar SH, Davit B, Chen ML, Conner D, Lee L, et al. (2008) Bioequivalence approaches for highly variable drugs and drug products. Pharm Res 25(3): 237–241.
16. Davit BM, Chen ML, Conner DP, Haidar SH, Kim S, et al. (2012) Implementation of a reference-scaled average bioequivalence approach for highly variable generic drug products by the US Food and Drug Administration. AAPS J 14(4): 915–924.
17. Food and Drug Administration. (2010) Draft Guidance on Progesterone. updated: December 12, 2012. Available: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM209294.pdf. Accessed: 2013 Oct 31.
18. Food and Drug Administration. (2012) Draft Guidance on Warfarin Sodium. Available: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM210283.pdf. Accessed: 2013 Oct 31.
19. Tothfalusi L, Endrenyi L (2012) Sample sizes for designing bioequivalence studies for highly variable drugs. J Pharm Sci 11(1): 73–84.
20. Owen RT (2009) Agomelatine: a novel pharmacological approach to treating depression. Drugs Today (Barc) 45(6): 599–606.
21. Song L, Du Q, Jiang X, Wang L (2014) Effect of CYP1A2 polymorphism on the pharmacokinetics of agomelatine in Chinese healthy male volunteers. J Clin Pharm Ther 39(2): 204–209.